338 related articles for article (PubMed ID: 14633992)
1. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer.
Ballestar E; Paz MF; Valle L; Wei S; Fraga MF; Espada J; Cigudosa JC; Huang TH; Esteller M
EMBO J; 2003 Dec; 22(23):6335-45. PubMed ID: 14633992
[TBL] [Abstract][Full Text] [Related]
2. A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer.
Lopez-Serra L; Ballestar E; Fraga MF; Alaminos M; Setien F; Esteller M
Cancer Res; 2006 Sep; 66(17):8342-6. PubMed ID: 16951140
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
Stirzaker C; Song JZ; Davidson B; Clark SJ
Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
[TBL] [Abstract][Full Text] [Related]
4. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells.
Lin X; Nelson WG
Cancer Res; 2003 Jan; 63(2):498-504. PubMed ID: 12543808
[TBL] [Abstract][Full Text] [Related]
5. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
6. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger.
Ballestar E; Esteller M
Biochem Cell Biol; 2005 Jun; 83(3):374-84. PubMed ID: 15959563
[TBL] [Abstract][Full Text] [Related]
7. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins.
Lopez-Serra L; Ballestar E; Ropero S; Setien F; Billard LM; Fraga MF; Lopez-Nieva P; Alaminos M; Guerrero D; Dante R; Esteller M
Oncogene; 2008 Jun; 27(25):3556-66. PubMed ID: 18223687
[TBL] [Abstract][Full Text] [Related]
8. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers.
Conway KE; McConnell BB; Bowring CE; Donald CD; Warren ST; Vertino PM
Cancer Res; 2000 Nov; 60(22):6236-42. PubMed ID: 11103776
[TBL] [Abstract][Full Text] [Related]
9. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays.
Yan PS; Chen CM; Shi H; Rahmatpanah F; Wei SH; Caldwell CW; Huang TH
Cancer Res; 2001 Dec; 61(23):8375-80. PubMed ID: 11731411
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of the methyl-CpG-binding domain of the methylation-dependent transcriptional repressor MBD1.
Ohki I; Shimotake N; Fujita N; Nakao M; Shirakawa M
EMBO J; 1999 Dec; 18(23):6653-61. PubMed ID: 10581239
[TBL] [Abstract][Full Text] [Related]
12. DNA binding of methyl-CpG-binding protein MeCP2 in human MCF7 cells.
Koch C; Strätling WH
Biochemistry; 2004 May; 43(17):5011-21. PubMed ID: 15109260
[TBL] [Abstract][Full Text] [Related]
13. Analysis of chromatin-immunopurified MeCP2-associated fragments.
El-Osta A; Wolffe AP
Biochem Biophys Res Commun; 2001 Dec; 289(3):733-7. PubMed ID: 11726209
[TBL] [Abstract][Full Text] [Related]
14. Tight interaction between densely methylated DNA fragments and the methyl-CpG binding domain of the rat MeCP2 protein attached to a solid support.
Shiraishi M; Sekiguchi A; Chuu YH; Sekiya T
Biol Chem; 1999 Sep; 380(9):1127-31. PubMed ID: 10543452
[TBL] [Abstract][Full Text] [Related]
15. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome.
Weber M; Hellmann I; Stadler MB; Ramos L; Pääbo S; Rebhan M; Schübeler D
Nat Genet; 2007 Apr; 39(4):457-66. PubMed ID: 17334365
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
[TBL] [Abstract][Full Text] [Related]
17. Treatment of tumor cells with histone deacetylase inhibitors results in altered recruitment of methyl-CpG binding proteins to a methylated CpG island.
Koizume S; Tachibana K; Shiraishi M
Biol Chem; 2003 May; 384(5):787-90. PubMed ID: 12817475
[TBL] [Abstract][Full Text] [Related]
18. Methyl-CpG binding proteins in the nervous system.
Fan G; Hutnick L
Cell Res; 2005 Apr; 15(4):255-61. PubMed ID: 15857580
[TBL] [Abstract][Full Text] [Related]
19. Methyl CpG binding proteins: coupling chromatin architecture to gene regulation.
Wade PA
Oncogene; 2001 May; 20(24):3166-73. PubMed ID: 11420733
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
